01:46 , Feb 2, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer; skin cancer Mouse studies suggest combining anti- PD-L1 therapies and promoters of reactive oxygen species (ROS) production or agonists of the mTOR or AMPK signaling pathways could help treat colorectal and skin...
07:00 , Jun 9, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Nuclear factor (erythroid-derived 2)-like 2 (NFE2L2; NRF2)

Other INDICATION: Progeria Patient sample, cell culture and mouse studies suggest promoting NFE2L2 activity could help treat Hutchinson-Gilford progeria syndrome (HGPS). In patient fibroblasts, NFE2L2 activity was lower than in fibroblasts from healthy volunteers. Also...
07:00 , Jun 30, 2008 |  BC Week In Review  |  Clinical News

CB1400: Phase II start

This quarter, Canopus will begin a South African Phase II trial of oral CB1400 in about 30 cancer patients. Canopus BioPharma Inc. (Pink:CBIA), Studio City, Calif.   Product: CB1400   Business: Other   Molecular target:...
07:00 , Jun 23, 2008 |  BC Week In Review  |  Clinical News

Canopus preclinical data

In mouse models of lung cancer, CB1400 plus cisplatin inhibited tumor growth by 70% vs. 62% for CB1400 alone and 49% for cisplatin alone. In a separate mouse study, CB1400 plus Erbitux cetuximab inhibited tumor...
07:00 , Jun 23, 2008 |  BC Week In Review  |  Company News

Canopus, WARF deal

WARF granted Canopus exclusive rights to IP covering the company’s CB1400 , which is in Phase II testing to treat mucositis in patients receiving radiotherapy or chemotherapy. Further terms were not disclosed. Canopus BioPharma Inc....
08:00 , Nov 5, 2007 |  BC Week In Review  |  Clinical News

Canopus preclinical data

In vitro, CB5300 was not inferior to marketed HCV drugs. CB5300 inhibits flaviviruses, the class of viruses to which HCV belongs. Canopus BioPharma Inc. (CBIA), Studio City, Calif.   Product: CB5300   Indication: Treat hepatitis...
08:00 , Nov 5, 2007 |  BC Week In Review  |  Clinical News

CB5300: Phase II start

In the next 6 months, CBIA will begin Phase II trials of CB5300. Canopus BioPharma Inc. (CBIA), Studio City, Calif.   Product: CB5300   Business: Infectious   Molecular target: NA   Description: Antiviral drug candidate...
07:00 , Oct 15, 2007 |  BC Week In Review  |  Clinical News

SpirH: Phase II started

CBIA began a South African Phase II trial of SpirH in 30 treatment-naïve patients. Canopus BioPharma Inc. (CBIA), Studio City, Calif.   Product: SpirH   Business: Infectious   Molecular target: NA   Description: Synthetic steroidal...
07:00 , Jul 23, 2007 |  BC Week In Review  |  Company News

Drake Holding Corp. infectious, cancer, neurology news

The company changed its name to Canopus BioPharma Inc. and changed its ticker to CBIA. Drake Holding Corp. (DRKH), Los Angeles, Calif.   Business: Infectious, Cancer, Neurology  ...